These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 22095536)
1. Predictive value of early viral dynamics during peginterferon and ribavirin combination therapy based on genetic polymorphisms near the IL28B gene in patients infected with HCV genotype 1b. Toyoda H; Kumada T; Tada T; Hayashi K; Honda T; Katano Y; Goto H; Kawaguchi T; Murakami Y; Matsuda F J Med Virol; 2012 Jan; 84(1):61-70. PubMed ID: 22095536 [TBL] [Abstract][Full Text] [Related]
2. Baseline factors and early viral response (week 4) to antiviral therapy with peginterferon and ribavirin for predicting sustained virologic response in patients infected with hepatitis C virus genotype 1: a multicenter study. Toyoda H; Kumada T; Shimada N; Takaguchi K; Ide T; Sata M; Ginba H; Matsuyama K; Izumi N J Med Virol; 2013 Jan; 85(1):65-70. PubMed ID: 23154876 [TBL] [Abstract][Full Text] [Related]
3. Impact of genetic polymorphisms near the IL28B gene and amino acid substitutions in the hepatitis C virus core region on interferon sensitivity/resistance in patients with chronic hepatitis C. Toyoda H; Kumada T; Tada T; Kawaguchi T; Murakami Y; Matsuda F J Med Virol; 2011 Jul; 83(7):1203-11. PubMed ID: 21567424 [TBL] [Abstract][Full Text] [Related]
4. Association of IL28B genotype and viral response of hepatitis C virus genotype 2 to interferon plus ribavirin combination therapy. Akuta N; Suzuki F; Seko Y; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H J Med Virol; 2012 Oct; 84(10):1593-9. PubMed ID: 22930507 [TBL] [Abstract][Full Text] [Related]
5. Antiviral combination therapy with peginterferon and ribavirin does not induce a therapeutically resistant mutation in the HCV core region regardless of genetic polymorphism near the IL28B gene. Toyoda H; Kumada T; Hayashi K; Honda T; Katano Y; Goto H; Kawaguchi T; Murakami Y; Matsuda F J Med Virol; 2011 Sep; 83(9):1559-64. PubMed ID: 21739446 [TBL] [Abstract][Full Text] [Related]
6. Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin. Scherzer TM; Hofer H; Staettermayer AF; Rutter K; Beinhardt S; Steindl-Munda P; Kerschner H; Kessler HH; Ferenci P J Hepatol; 2011 May; 54(5):866-71. PubMed ID: 21145807 [TBL] [Abstract][Full Text] [Related]
7. Association of two polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus. Kobayashi M; Suzuki F; Akuta N; Sezaki H; Suzuki Y; Hosaka T; Kawamura Y; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Chayama K; Miyakawa Y; Kumada H J Gastroenterol; 2012 May; 47(5):596-605. PubMed ID: 22438096 [TBL] [Abstract][Full Text] [Related]
8. Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype. Itokawa N; Atsukawa M; Tsubota A; Kondo C; Hashimoto S; Fukuda T; Matsushita Y; Kidokoro H; Kobayashi T; Narahara Y; Nakatsuka K; Kanazawa H; Iwakiri K; Sakamoto C J Gastroenterol Hepatol; 2013 Mar; 28(3):443-9. PubMed ID: 23173698 [TBL] [Abstract][Full Text] [Related]
9. Impact of hepatitis B virus integration into liver tissue on the efficacy of peginterferon and ribavirin therapy in hepatitis B virus-negative chronic hepatitis C patients. Toyoda H; Kumada T; Tada T; Murakami Y J Clin Gastroenterol; 2014 Jan; 48(1):73-9. PubMed ID: 23842217 [TBL] [Abstract][Full Text] [Related]
10. Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy. Aziz H; Raza A; Ali K; Khattak JZ; Irfan J; Gill ML Int J Infect Dis; 2015 Jan; 30():91-7. PubMed ID: 25462177 [TBL] [Abstract][Full Text] [Related]
11. Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin. Huang CF; Huang JF; Yang JF; Hsieh MY; Lin ZY; Chen SC; Wang LY; Juo SH; Chen KC; Chuang WL; Kuo HT; Dai CY; Yu ML J Hepatol; 2012 Jan; 56(1):34-40. PubMed ID: 21703176 [TBL] [Abstract][Full Text] [Related]
12. IL28B polymorphisms predict response to therapy among chronic hepatitis C patients with HCV genotype 4. Antaki N; Bibert S; Kebbewar K; Asaad F; Baroudi O; Alideeb S; Hadad M; Abboud D; Sabah H; Bochud PY; Negro F J Viral Hepat; 2013 Jan; 20(1):59-64. PubMed ID: 23231085 [TBL] [Abstract][Full Text] [Related]
13. IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection. Moghaddam A; Melum E; Reinton N; Ring-Larsen H; Verbaan H; Bjøro K; Dalgard O Hepatology; 2011 Mar; 53(3):746-54. PubMed ID: 21374656 [TBL] [Abstract][Full Text] [Related]
14. Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment response. Clark PJ; Thompson AJ; Zhu M; Vock DM; Zhu Q; Ge D; Patel K; Harrison SA; Urban TJ; Naggie S; Fellay J; Tillmann HL; Shianna K; Noviello S; Pedicone LD; Esteban R; Kwo P; Sulkowski MS; Afdhal N; Albrecht JK; Goldstein DB; McHutchison JG; Muir AJ; J Viral Hepat; 2012 May; 19(5):332-40. PubMed ID: 22497812 [TBL] [Abstract][Full Text] [Related]
15. HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy. Hayes CN; Kobayashi M; Akuta N; Suzuki F; Kumada H; Abe H; Miki D; Imamura M; Ochi H; Kamatani N; Nakamura Y; Chayama K Gut; 2011 Feb; 60(2):261-7. PubMed ID: 21068134 [TBL] [Abstract][Full Text] [Related]
16. IL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1. Lindh M; Lagging M; Arnholm B; Eilard A; Nilsson S; Norkrans G; Söderholm J; Wahlberg T; Wejstål R; Westin J; Hellstrand K J Viral Hepat; 2011 Jul; 18(7):e325-31. PubMed ID: 21692944 [TBL] [Abstract][Full Text] [Related]
17. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin. Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916 [TBL] [Abstract][Full Text] [Related]
18. Predictive factors for 24 weeks sustained virologic response (SVR24) and viral relapse in patients treated with simeprevir plus peginterferon and ribavirin. Nakayama M; Kobayashi H; Fukushima K; Ishido M; Komada Y; Yoshizawa K Hepatol Int; 2016 Jan; 10(1):158-68. PubMed ID: 26264253 [TBL] [Abstract][Full Text] [Related]
19. Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b. Hashimoto Y; Ochi H; Abe H; Hayashida Y; Tsuge M; Mitsui F; Hiraga N; Imamura M; Takahashi S; Nelson Hayes C; Ohishi W; Kubo M; Tsunoda T; Kamatani N; Nakamura Y; Chayama K J Med Virol; 2011 Jun; 83(6):981-8. PubMed ID: 21503910 [TBL] [Abstract][Full Text] [Related]
20. An open-label randomized controlled study of pegylated interferon/ribavirin combination therapy for chronic hepatitis C with versus without fluvastatin. Kondo C; Atsukawa M; Tsubota A; Itokawa N; Fukuda T; Matsushita Y; Kidokoro H; Kobayashi T; Narahara Y; Nakatsuka K; Kanazawa H; Sakamoto C J Viral Hepat; 2012 Sep; 19(9):615-22. PubMed ID: 22863265 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]